Fig. 1 · Structure

Documents & Downloads

Diosmin

Cat. No. A10317 CAS 520-27-4
Diosmin is a semisynthetic phlebotropic agent and a member of the flavonoid family.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In HA22T hepatocellular carcinoma cells, PP2A inhibition or knockdown attenuated diosmin-associated apoptosis-marker changes. This supports cellular PP2A involvement; it does not establish direct PP2A binding or catalytic activation. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 40 μM Antiproliferative activity against human A549 cells after 72 hrs by Alamar blue assay [PMID: 27374881]
C2C12 IC50 19.97 μg/mL Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay [PMID: 33412152]
MDA-MB-231 IC50 70 μM Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay [PMID: 27374881]
Monocyte IC50 > 200 μM Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA [PMID: 10096854]
SK-BR-3 IC50 > 100 μM Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay [PMID: 27374881]
T47D IC50 > 100 μM Antiproliferative activity against human T47D cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay [PMID: 27374881]

Diosmin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Diosmin from 3 published references. In vitro models include human HA22T hepatocellular carcinoma cells; mouse C2C12 myoblasts in growth medium.

Diosmin In Vitro Studies

Diosmin increased proliferation-related readouts in C2C12 myoblasts. Continuous exposure during differentiation reduced MyHC expression, showing that the exposure schedule and differentiation state matter when interpreting its cellular effects. [2]

PP2A perturbation of diosmin-associated apoptosis markers

Cell-based study · Human HA22T hepatocellular carcinoma cells [1]

Okadaic acid and PP2A-Cα siRNA opposed diosmin-associated apoptosis-marker changes. This supports cellular PP2A involvement, without establishing direct binding or purified-enzyme activation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PP2A-Cα, t-BID, Bcl-2, Bax, cytochrome c and caspase-9/-3 protein patternsqualitative response PP2A inhibition or knockdown attenuated diosmin-associated marker changes[1]

Literature-Reported Treatment Conditions

Treatment concentration
80 µM
Exposure duration
24 h diosmin; okadaic acid pretreatment 1 h
Method
Western blot after pharmacological or siRNA perturbation
Vehicle
DMSO; final concentration never exceeded 0.1%
Co-treatment
Okadaic acid 0.05 or 0.1 nM; PP2A-Cα siRNA 100 or 120 nM; non-targeting siRNA 100 nM.
Reported limits
No direct PP2A catalytic-activity or binding measurement in this experiment. Exact figure-specific transfection-to-treatment interval is not resolved from shared methods.
Methods and source locations

Compound reported in the paper: Diosmin; Compound label in the paper: Sigma diosmin, CAS 520-27-4, >95% pure

Restricted to the reported material and model; no Adooq lot equivalence or human efficacy established.

Sections 2.1–2.3, 2.7, 2.9, 2.12, 3.3–3.4; Fig. 4A–F, p. 2069

PP2A-Cα, t-BID, Bcl-2, Bax, cytochrome c and caspase-9/-3 protein patterns: Western blot, α-tubulin loading control; non-targeting siRNA control; mean ± SE, n = 3 as reported. — Fig. 4A–F; sections 3.3–3.4

C2C12 proliferation during diosmin exposure

Cell-based study · Mouse C2C12 myoblasts in growth medium [2]

Diosmin increased CCK-8 viability at 10, 50 and 100 µM; no difference between 50 and 100 µM was reported. At 50 µM, EdU labeling and the S-phase fraction increased.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCK-8 viability, EdU-positive cells and cell-cycle distributionqualitative response Viability increased at 10–100 µM; 50 versus 100 µM: no difference reported. EdU-positive fraction and S phase increased at 50 µM.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 5, 10, 50 and 100 µM for CCK-8; 50 µM for EdU/cell cycle
Exposure duration
24 h
Method
Culture exposure in high-glucose DMEM with 10% fetal bovine serum
Vehicle
DMSO; final concentration not reported
Reported limits
The 0 µM control is shown, but explicit vehicle matching is not stated. n is given per assay; biological independence is not defined.
Methods and source locations

Compound reported in the paper: Diosmin; Compound label in the paper: Selleck diosmin, dissolved in DMSO

Restricted to the reported material and model; no Adooq lot equivalence or human efficacy established.

Materials and Methods: Cell Culture and Treatment, CCK-8, Cell Proliferation, Cell Cycle, Western Blot, Statistics; Results first subsection; Fig. 1A–J

CCK-8 viability, EdU-positive cells and cell-cycle distribution: CCK-8 n = 6; EdU/flow cytometry n = 3; mean ± SEM. Fig. 1F is a cell-cycle plot despite an erroneous CCK-8 axis label. — Fig. 1B, E–F, I–J and first Results subsection

Continuous diosmin exposure during C2C12 differentiation

Cell-based study · C2C12 myoblasts in differentiation medium with 2% horse serum [2]

Continuous exposure reduced MyHC protein at 5–50 µM on days 3 and 5. At 50 µM, MyHC-positive nuclei were reduced on day 5. Day-5 MyOG protein was unaffected at 5 and 50 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MyHC and MyOG protein; MyHC-positive nucleiqualitative response MyHC protein decreased at days 3 and 5; MyHC-positive nuclei decreased at 50 µM on day 5. Day-5 MyOG at 5 and 50 µM: no effect reported.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 5, 10 and 50 µM; immunofluorescence/time course: 50 µM
Exposure duration
3 or 5 days for concentration comparisons; time course 0, 2, 4, 6 and 8 days; day-5 immunofluorescence
Method
Continuous exposure during differentiation
Vehicle
DMSO; final concentration not reported
Reported limits
Explicit vehicle matching not stated. Fig. 5 uses a separate pretreatment-then-withdrawal design with a different outcome; that design is not represented by this study.
Methods and source locations

Compound reported in the paper: Diosmin; Compound label in the paper: Selleck diosmin, dissolved in DMSO

Restricted to the reported material and model; no Adooq lot equivalence or human efficacy established.

Materials and Methods: Cell Culture and Treatment, Western Blot, qRT-PCR, Immunofluorescence; Results: Diosmin Inhibits the Differentiation of C2C12 Myoblasts; Fig. 4A–J

MyHC and MyOG protein; MyHC-positive nuclei: Western blot with GAPDH loading control, MyHC immunofluorescence; n = 3, mean ± SEM. — Fig. 4A–F and I–J; corresponding Results subsection

Diosmin In Vivo Studies

Two commercial diosmin tablet preparations reduced vascular leakage and altered perfusion in mice with iliac vein stenosis after 28 days of oral treatment. Their different performance is formulation-specific and cannot be assigned to A10317. Unchanged serum ALT, AST and creatinine provide only limited tolerability information. [3]

Diosmin tablet preparations in mouse iliac vein stenosis

Animal study · Male C57BL/6 mice, 8 weeks old; iliac vein stenosis and sham controls [3]

Both commercial preparations reduced stenosis-associated increases in hindlimb perfusion ratio and Evans blue leakage; preparation A performed better than B. No significant serum ALT, AST or creatinine change was reported at day 28; these measures do not establish general organ safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Left/right hindlimb perfusion ratio and muscle Evans blue leakagequalitative response Both preparations reduced stenosis-associated increases; A outperformed B. No stenosis-versus-sham perfusion difference was reported on postoperative day 1.[3]
Serum ALT, AST and creatinine at day 28qualitative response No significant difference reported after either preparation[3]

Conditions shared by the study groups

Route
Intragastric
Frequency
Once daily
Treatment course
28 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Commercial diosmin preparation A
40 mg/kg
IVS/normal saline, sham/normal saline and sham/preparation groupsReduced perfusion-ratio elevation and Evans blue leakage; better than B; no significant ALT, AST or creatinine change reported.[3]
Commercial diosmin preparation B
40 mg/kg
IVS/normal saline, sham/normal saline and sham/preparation groupsReduced perfusion-ratio elevation and Evans blue leakage; less effective than A; no significant ALT, AST or creatinine change reported.[3]
Commercial diosmin preparation A
Model: Male C57BL/6 iliac vein stenosis mice
Reported limits: Tablet excipients and drug vehicle unspecified; no PK comparison or control isolating impurity effects.
Commercial diosmin preparation B
Model: Male C57BL/6 iliac vein stenosis mice
Reported limits: Tablet excipients and drug vehicle unspecified; no PK comparison or control isolating impurity effects.
Methods and source locations

Compound reported in the paper: Diosmin; Compound label in the paper: Commercial diosmin tablets A (reported purity 99%) and B (95%)

Formulation-specific preclinical evidence; no transfer of relative performance to A10317.

Materials and Methods: Mouse Model of IVS, HPLC, Laser Speckle Images, Evans Blue, ELISA, Statistics; Results; Figs. 1, 2A–D, 5A–C

Left/right hindlimb perfusion ratio and muscle Evans blue leakage: Laser speckle imaging at postoperative, day 14 and day 28; Evans blue day 28. Mean ± SD. Perfusion n: sham 3 each, IVS/NS 6, IVS/A and IVS/B 7 each; Evans blue n: sham 3 each, IVS groups 6 each. — Fig. 2A–D; Results: Blood Perfusion and Vascular Leakage

Serum ALT, AST and creatinine at day 28: ELISA; mean ± SD; sham n = 3 each, IVS/NS n = 6, IVS/A and IVS/B n = 7 each. Serum technical duplicates were averaged. — ELISA Assay; Fig. 5A–C; Results: Diosmin Did Not Cause Kidney or Liver Damage

Commercial diosmin preparation A · Mouse Model of IVS; HPLC Results; Figs. 1, 2, 5

Commercial diosmin preparation B · Mouse Model of IVS; HPLC Results; Figs. 1, 2, 5

Specifications

Manufacturer Adooq Bioscience
CAS Number 520-27-4
Formula C28H32O15
Molecular Weight 608.5
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 5 mg/mL (8.21 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Diosmin Research References

  1. [1] Tran Duc Dung, Chih-Hsueh Lin, Truong Viet Binh, et al. Diosmin induces cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and blocks tumour growth in xenografted nude mice Food Chemistry (2012). DOI: 10.1016/j.foodchem.2011.11.149 Source material
  2. [2] Dingding Zhang, Xuan Zhang, Zhaojun Liu, et al. Diosmin Promotes Myogenesis via Activating the Akt/FOXO1 Pathway to Facilitate the Proliferation of C2C12 Myoblasts Journal of Agricultural and Food Chemistry (2023). PMID: 38029323 DOI: 10.1021/acs.jafc.3c04828 Source material
  3. [3] Junjie Zou, Dongping Yuan, Jin Yang, et al. Effects of Diosmin on Vascular Leakage and Inflammation in a Mouse Model of Venous Obstruction Frontiers in Nutrition (2022). PMID: 35273990 DOI: 10.3389/fnut.2022.831485 Source material

Added to your cart

View Cart Checkout
Loading...